Cladribine combined with cyclophosphamide and mitoxantrone is an active salvage therapy in advanced non-Hodgkin's lymphoma

Leukemia and Lymphoma

Volumn 48, Issue 6, 2007, Pages 1092-1101

  Robak, Tadeusz ^a   Lech Maranda, Ewa ^a   Janus, Agnieszka ^a   Blonski, Jerzy ^a   Wierzbowska, Agnieszka ^a   Gora Tybor, Joanna ^a  

^a MEDICAL UNIVERSITY OF LODZ   (Poland)

Author keywords

2 CdA; Cyclophosphamide; DLBCL; Lymphoma; MCL; Mitoxantrone

Indexed keywords

BLEOMYCIN; CLADRIBINE; CYCLOPHOSPHAMIDE; CYTARABINE; DEXAMETHASONE; DOXORUBICIN; IDARUBICIN; MITOXANTRONE; PREDNISONE; VINCRISTINE;

ADULT; ADVANCED CANCER; AGED; ALOPECIA; ANEMIA; ARTICLE; B CELL LYMPHOMA; BACTERIAL PNEUMONIA; BONE MARROW SUPPRESSION; CANCER RECURRENCE; CANCER REGRESSION; CANCER RELAPSE; CANCER SURVIVAL; CHEMOTHERAPY INDUCED EMESIS; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG EFFICACY; DRUG FEVER; DRUG RESPONSE; DRUG SAFETY; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; FEASIBILITY STUDY; FEMALE; FLU LIKE SYNDROME; FOLLICULAR LYMPHOMA; FOLLOW UP; HERPES ZOSTER; HUMAN; INFECTION; LARGE CELL LYMPHOMA; LYMPHOCYTOMA; MALE; MANTLE CELL LYMPHOMA; MULTIPLE CYCLE TREATMENT; NEUTROPENIA; NONHODGKIN LYMPHOMA; OVERALL SURVIVAL; PNEUMONIA; PRIORITY JOURNAL; SALVAGE THERAPY; STATISTICAL SIGNIFICANCE; SURVIVAL RATE; SURVIVAL TIME; T CELL LYMPHOMA; THROMBOCYTOPENIA;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CLADRIBINE; CYCLOPHOSPHAMIDE; FEASIBILITY STUDIES; FEMALE; HUMANS; LYMPHOMA, NON-HODGKIN; MALE; MIDDLE AGED; MITOXANTRONE; SALVAGE THERAPY; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 34347383853     PISSN: 10428194     EISSN: 10292403     Source Type: Journal    
DOI: 10.1080/10428190701361216     Document Type: Article

References (43)

1. Robak, T., Korycka, A., Kasznicki, M., Wrzesien-Kus, A. and Smolewski, P. (2005) Purine nucleoside analogues for the treatment of hematological malignancies: Pharmacology and clinical applications. Curr Cancer Drug Targets, 5, pp. 424-444.
2. Tallman, M. S. and Hakimian, D. (1995) Purine nucleoside analogs: emerging roles in indolent lymphoproliferative disorders. Blood, 86, pp. 2463-2474.
3. Kay, A. C., Saven, A., Carrera, C. J., Carson, D. A., Thurston, D. and Beutler, E. (1992) 2-chlorodeoxyadenosine treatment of low-grade non-Hodgkin's lymphomas. J Clin Oncol, 10, pp. 371-377.
4. Betticher, D. C., von Rohr, A., Ratschiller, D., Schmitz, S. F., Egger, T. and Sonderegger, T. (1998) Fewer infections but maintained antitumor activity with lower-dose versus standard dose caldribine in pretreated low grade non-Hodgkin's lymphoma. J Clin Oncol, 16, pp. 850-859.
5. Liliemark, J., Porwit, A. and Juliusson, G. (1997) Intermittent infusion cladribine (CdA) in previously treated patients with low-grade non-Hodkin's lymphoma. Leuk Lymphoma, 25, pp. 313-318.
6. Robak, T., Góra-Tybor, J., Krykowski, E., Walewski, J. A., Borawska, A. and Płuzańska, A. (1997) Activity of 2-chlorodeoxyadenosine (Cladribine) in 2-hour intravenous infusion in 94 previously treated patients with low-grade non-Hodgkin's lymphoma. Leuk Lymphoma, 26, pp. 99-105.
7. Tulpule, A., Schiller, G., Harvey-Buchanan, L. A., Lee, M., Espina, B. M. and Khan, A. U. (1998) Cladribine in the treatment of advanced relapsed or refractory low and intermediate grade non-Hodgkin's lymphoma. Cancer, 83, pp. 370-376.
8. Ogura, M., Morishima, Y., Kobayashi, Y., Uike, N., Sugai, S. and Chou, T. (2004) Durable response but prolonged cytopenia after cladribine treatment in relapsed patients with indolent non-Hodgkin's lymphomas: results of Japanese phase II study. Int J Haematol, 80, pp. 267-277.
9. Rummel, M. J., Chow, K. U., Jager, E., Leimer, L., Hossteld, D. K. and Bergmann, L. (1999) Intermittent 2-hour infusion of cladribine as first-line therapy or in first relapse of progressive advanced low-grade and mantle cell lymphomas. Leuk Lymphoma, 82, pp. 957-964.
10. Rummel, M. J., Chow, K. U., Jager, E., Hossfeld, D. K., Bergmann, L. and Peters, H. D. (1999) Treatment of mantle-cell lymphomas with intermittent two-hour infusion of cladribine as first-line therapy or in first relapse. Ann Oncol, 10, pp. 115-117.
11. Kong, L. R., Huang, C. F., Hakimian, D., Variakojis, D., Klein, L. and Kuzel, T. M. (1998) Long term follow-up and late complications of 2-chlorodeoxyadenosine in previously treated, advanced indolent non-Hodgkin's lymphoma. Cancer, 82, pp. 957-964.
12. Saven, A., Emanuele, S., Kosty, M., Kozioł, J., Ellison, D. and Piro, L. (1995) 2-chlorodeoxyadenosine activity in patients with utreated indolent non-Hodgkin's lymphoma. Blood, 86, pp. 1710-1716.
13. Fridrik, M., Jager, G., Kienzer, H. R., Hausmaninger, H., Oppitz, P. and Krieger, O. (1998) Efficacy and toxicity of 2-chlorodeoxyadenosine (Cladribine)- 2 h infusion for 5 days - as first-line treatment for advanced low-grade non-Hodgkin's lymphoma. Eur J Cancer, 34, pp. 1560-1564.
14. Neste, E Van Den, Bontemps, F., Delacauw, A., Cardoen, S., Louviaux, I. and Scheiff, J. M. (1999) Potentiation of antitumor effects of cyclophosphamide derivatives in B-chronic lymphocytic leukemia cells by 2-chloro-2'-deoxyadenosine. Leukemia, 13, pp. 918-925.
15. Góra-Tybor, J. and Robak, T. (1993) Synergistic action of 2-chlorodeoxyadenosine and cyclophosphamide on murine leukemia L1210 and P388. Acta Haematol Pol, 24, pp. 177-182.
16. Hoffman, M., Xu, J. C., Lesser, M. and Rai, K. (1999) Cytotoxicity of 2-chlorodeoxyadeosine (cladribine - 2-CdA) in combination with other chemotherapy drugs against two lymphoma cell lines. Leuk Lymphoma, 33, pp. 141-145.
17. Szmigielska-Kapłon, A., Ciesielska, E., Smigiero, L. and Robak, T. (2002) Anthracyclines potentiate activity against murine leukemias L1210 and P388 in vivo and in vitro. Eur J Haematol, 68, pp. 370-375.
18. Laurencet, F. M., Ballabeni, P., Rufener, B., Hess, U., Cerny, T. and Fey, M. (2007) The multicenter trial SAKK 37/95 of cladribine, cyclophosphamide and prednisone in the treatment of chronic lymphocytic leukemias and low-grade non-Hodgkin's lymphomas. Acta Haematol, 117, pp. 40-47.
19. Neste, E Van den, Louviaux, I., Michaux, J. L., Delnnoy, A., Michaux, L. and Sonet, A. (2000) Phase I/II study of 2-chloro-2-deoxyadenosine with cyclophosphamide in patients with pretreated B-cell chronic lymphocytic leukemia and indolent non-Hodgkin's lymphoma. Leukemia, 14, pp. 1136-1142.
20. Kalinka, E., Wajs, J. J., Sułek, K. S., Blasinska-Morawiec, M., Centkowski, P. and Ceglarek, B. (2006) Randomized comparison of cladribine single (C) or in combination with cyclophosphamide (CC) and COP in previously untreated low-grade B-cell non-Hodgkin lymphoma patients. Blood, 108, p. 703a.
21. Robak, T., Góra-Tybor, J., Urbanska-Rys, H. and Krykowski, E. (1999) Combination regimen of 2-chlorodeoxyadenosine (cladribine), mitoxantrone and dexamethasone (CMD) in the treatment of refractory and recurrent low-grade non Hodgkin's lymphoma. Leuk Lymphoma, 32, pp. 359-368.
22. Armitage, J. O., Tobinai, K., Hoelzer, D. and Rummel, M. J. (2004) Treatment of indolent non-Hodgkin's lymphoma with cladribine as single-agent therapy and in combination with mitoxantrone. Int J Hematol, 79, pp. 311-321.
23. Rummel, M. J., Chow, K. U., Karakas, T., Jager, E., Mezger, J. and von Grunhagen, U. (2002) Reduced dose cladribine (2-CdA) plus mitoxantrone is effective in the treatment of mantle cell and low-grade non-Hodgkin's lymphoma. Eur J Cancer, 38, pp. 1739-1746.
24. Robak, T., Góra-Tybor, J. and Chojnowski, K. (2000) Cladribine as monotherapy or combined with dexamethasone and idarubicin or mitoxantrone in previously treated patients with low grade lymphoid malignancies. Haematologica, 85, pp. 215-216.
25. Robak, T., Błoński, J. Z., Kasznicki, M., Góra-Tybor, J., Dwilewicz-Trojaczek, J. and Boguradzki, P. (2001) Cladribine combined with cyclophosphamide and mitoxantrone as front-line therapy in chronic lymphocytic leukemia. Leukemia, 15, pp. 1510-1516.
26. Robak, T., Błoński, J. Z., Góra-Tybor, J., Jamroziak, K., Dwilewicz-Trojaczek, J. and Tomaszewska, A. (2006) Cladribine alone and in combination with cyclophosphamide or cyclophosphamide plus mitoxantrone in the treatment of progressive chronic lymphocytic leukemia: Report of a prospective, multicenter randomized trial of the Polish Adults Leukemia Group (PALG CLL 2). Blood, 108, pp. 473-479.
27. Robak, T., Góra-Tybor, J., Lech-Maranda, E., Błoński, J. Z. and Kasznicki, M. (2000) Cladribine in combination with mitoxantrone and cyclophsophamide (CMC) in the treatment of heavily pretreated patients with advanced indolent lymphoid malignancies. Eur J Haematol, 66, pp. 188-194.
28. Cheson, B. D., Horning, S. J., Coiffier, B., Shipp, M. S., Fisher, R. I. and Connors, J. M. (1999) Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. J Clin Oncol, 17, pp. 1244-1253.
29. Miller, A. B., Hoogstraten, B., Staquet, M. and Winkler, A. (1981) Reporting results of cancer treatment. Cancer, 47, pp. 207-214.
30. Duffy, D. R. and Santner, T. J. (1987) Confidence intervals binomial parameter based on multistage tests. Biometrics, 47, pp. 207-214.
31. Kaplan, E. L. and Meier, P. (1958) Nonparametric estimation from incomplete observations. J Am Stat Assoc, 53, pp. 457-481.
32. Cohen, B. J., Moskowitz, C., Straus, D., Noy, A., Mednick, E. and Zelenetz, A. (2001) Cyclophosphamide fludarabine (CCF) is active in the treatment of mantle cell lymphoma. Leuk Lymphoma, 42, pp. 1015-1022.
33. Thomas, D. W., Owen, R. G., Johnson, S AN, Hillmen, P., Seymour, J. F., Wolf, M. M. and Rule, S AJ (2005) Superior quality and duration of response among patients with mantle cell lymphoma treated with fludarabine and cyclophosphamide with or without rituximab compared with prior responses to CHOP. Leuk Lymphoma, 46, pp. 549-552.
34. Forspointer, R., Dreyling, M., Repp, R., Hermann, S., Hanel, A. and Metzner, B. (2004) The addition of rituximab to a combination of fludarabine, cyclophosphamide, mitoxantrone (FCM) significantly increases the response rate and prolongs survival as compared with FCM alone in patients with relapsed and refractory follicular and mantle cell lymphomas: Results of a prospective randomized study of the German Low-Grade Lymphoma Study Group. Blood, 104, pp. 3064-3071.
35. Robak, T., Smolewski, P., Cebula, B. and Blonski, J. Z. (2006) Rituximab combined with cladribine or with cladribine and cyclophosphamide in heavily pretreated patients with indolent lymphoproliferative disorders and mantle cell lymphoma. Cancer, 107, pp. 1542-1550.
36. Robak, T. (2005) Rituximab plus purine nucleoside analogs in the treatment of indolent lymphoid malignancies. Am J Cancer, 4, pp. 279-292.
37. Forspointner, R., Unterhalt, M., Dreyling, M., Bock, H. P., Repp, R. and Wandt, H. (2006) Maintenance therapy with rituximab leads to a significant prolongation of response duration after salvage therapy with a combination of rituximab, fludarabine, cyclophosphmide and mitoxantrone (R-FCM) in patients with recurring and refractory follicular and mantle cell lymphomas: Results of a prospective randomized study of the German Low Grade Lymphoma Study Group (GLSG). Blood, 108, pp. 4003-4008.
38. Redman, J. R., Cabanillas, F., Velasquez, W. S., Laughlin, P Mc, Hagemeister, F. B. and Swan Jr, F. (1992) Phase II trial of fludarabine phosphate in lymphoma an effective new agent in low-grade lymphoma. J Clin Oncol, 10, pp. 790-794.
39. Child, J. A., Johnson, S. A., Rule, S., Smith, G. M., Morgan, G. J. and Johnson, P. W. (2000) FLUDAP: Salvage chemotherapy for relapsed/ refractory aggressive non-Hodgkin's lymphoma. Leuk Lymphoma, 37, pp. 309-317.
40. Yamaguchi, M., Kotani, T., Nkamura, Y. and Ueda, M. (2006) Successful treatment of refractory peripheral T-cell lymphoma with a combination of fludarabine and cyclophosphamide. Int J Hematol, 83, pp. 450-453.
41. Villanueva, M. L. and Vose, J. M. (2006) The role of hematopoietic stem cell transplantation in non-Hodgkin lymphoma. Clin Adv Hematol Oncol, 4, pp. 521-530.
42. Van Besien, K. (2006) The evolving role of autologous and allogeneic stem cell transplantation in follicular lymphoma. Blood Rev, 20, pp. 235-244.
43. Laudi, N., Arora, M., Burns, L., McGlave, P., Miller, J. and Bohac, G. (2006) Efficacy of high-dose therapy and hematopoietic stem cell transplantation for mantle cell lymphoma. Am J Hematol, 81, pp. 519-524.